Aprea Therapeutics, Inc. Logo

Aprea Therapeutics, Inc.

Developing precision cancer therapies targeting DNA Damage Response for solid tumors.

APRE | NDAQ

Overview

Corporate Details

ISIN(s):
US03836J1025
LEI:
Country:
United States of America
Address:
3805 OLD EASTON ROAD, 18902 DOYLESTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics through precision oncology. The company specializes in synthetic lethality-based therapies that target DNA Damage Response (DDR) pathways. Aprea's pipeline features small molecule drug candidates designed to maximize clinical efficacy while minimizing toxicity. The company is actively conducting clinical trials to evaluate its programs in patients with advanced solid tumors, aiming to provide new treatment options and improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aprea Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprea Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprea Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CDT Equity Inc. Logo
Clinical-stage biopharma using AI to enhance and advance therapies for unmet medical needs.
United States of America CDT
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America CELC
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellectis S.A. Logo
Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.
United States of America CLLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.